Thiogamma Turbo solution for infusion 50ml vials №10

Thiogamma Turbo solution for infusion 50ml vials №10

Product Code: 6049
Availability: In Stock

Ask a question about this product


active substance:?-lipoic acid

50 ml of solution contain 1.2% megluminova salt of ?-lipoic acid 1167,7 mg (equivalent to 600 mg ?-lipoic acid)

excipients:meglumin, macrogol 300, water for injection.


Dosage form

Solution for infusion.

Basic physical and chemical properties:the solution is yellowish or greenish-yellow color.


drug description

agents affecting the digestive system and metabolic processes. A16a H01 ATH code.


Pharmacological properties


?-lipoic acid is a substance that is synthesized in the body and acts as coenzyme in oxidative decarboxylation of ?-keto acids; plays an important role in the formation of energy in the cell. Helps to reduce blood sugar and increase the amount of glycogen in the liver. The lack or the metabolism of ?-lipoic acid due to intoxication or excessive accumulation of certain decay products (e.g., ketone bodies) leads to disruption of aerobic glycolysis. ?-lipoic acid can exist in two physiologically active forms (oxidized and reduced) that have antitoxic and antioxidant action. ?-lipoic acid affects cholesterol metabolism, participates in regulation of lipid and carbohydrate metabolism, improves liver function (due to hepatoprotective, antioxidant, detoxification actions). ?-lipoic acid is similar in pharmacological properties to b vitamins.


?-lipoic acid undergoes significant changes in the primary passage through the liver. There are significant interindividual fluctuations in the systemic availability of ?-lipoic acid. It is excreted by the kidneys mainly in the form of metabolites. The formation of metabolites occurs as a result of oxidation of the side chain and conjugation. The half-life TiganaTurbo from serum is 10-20 minutes. 


disturbance of sensation in diabetic neuropathy.


hypersensitivity to ?-lipoic acid or other components of the drug . Heart and respiratory failure, acute phase of myocardial infarction, acute cerebrovascular accident, dehydration, chronic alcoholism and other conditions that can lead to lactic acidosis.

Interaction with other medicinal products and other forms of interaction.

?-lipoic acid reacts with ionic metal complexes (e.g. cisplatin), so TihamaTurbo may reduce the effect of cisplatin. With sugar molecules, ?-lipoic acid forms insoluble complex compounds. Thus, the solution of ?-lipoic acid is incompatible with glucose solution, ringer solution and solutions that may react with SH-groups or disulfide bonds.

Do not use in conjunction with preparations containing metals (e.g. iron, magnesium).

Thioctic acid can enhance the hypoglycemic effect of insulin and/or other antidiabetic agents, so especially at the beginning of treatment of thioctic acid, regular monitoring of blood sugar levels is indicated. To prevent the appearance of symptoms of hypoglycemia in some cases, it may be necessary to reduce the dose of insulin and/or oral antidiabetic agent.

Ethanol reduces the therapeutic efficacy of thioctic acid.

application features

When using the drug ThiogammaTurbo, you should apply light-proof black bags (see the Cardboard packaging) that fits on top of the vial when the drug is administered intravenously.

the main factor in the effective treatment of diabetic polyneuropathy optimal correction of blood sugar in the patient. 

When parenteral use of the drug ThiogammaTurbo there is a risk of allergic reactions, including anaphylactic shock, so patients should be checked for the presence of such reactions. In case of appearance of such symptoms as itching, nausea, malaise, should immediately stop the drug and to take appropriate therapeutic measures.

In rare patients with decompensated or inadequately controlled diabetes and worsening of General health status can develop serious anaphylactic reactions associated with the drug ThiogammaTurbo.

frequent blood glucose monitoring is required in the treatment of diabetics, especially at the beginning of treatment. In some cases, it is necessary to adjust the dose of antidiabetic agents to prevent hypoglycemia.

during the treatment of polyneuropathy, thanks to regenerative processes, perhaps a short-term increase in sensitivity, accompanied by paresthesia with a feeling of "creeping goosebumps".

Certain restrictions on the introduction of drugs thioctic acid is an elderly age (over 75 years).

Warning:regular alcohol consumption is a significant risk factor for the development and progression of the clinical picture of neuropathy and may therefore adversely affect the treatment process. Therefore, patients with diabetic polyneuropathy are usually recommended to refrain from drinking alcohol whenever possible. The restriction on alcohol consumption also applies to interruptions between courses of treatment.

use during pregnancy or lactation.

there is not enough experience in the use of the drug during pregnancy and lactation, so it should not be prescribed during these periods.

Ability to influence the reaction rate when driving motor transport or operating other mechanisms.

During application of the drug should be careful when driving and occupation of other potentially hazardous activities, require high concentration and speed of psychomotor reactions.

Method of application and doses

the Drug is administered directly from the bottle (i.e. without solvent) in the form of intravenous drip infusion at a dose of 600 mg per day (contents of 1 bottle) for at least 30 min.

due to the fact that ?-lipoic acid is sensitive to the action of light, the bottles should be stored in cardboard packaging prior to their direct application.

At the beginning of the treatment, the drug ThiogammaTurbo injected. The course of treatment - 2-4 weeks.

for further therapy, use oral forms of thioctic acid preparations at a dose of 300-600 mg per day.


the Efficacy and safety of the drug in children have not been established, so it should not be prescribed to this age group of patients.


Symptoms:nausea, vomiting and headache. When applying very high doses of 10 to 40 g of thioctic acid in combination with alcohol, severe intoxication is observed, which can lead to death. The clinical picture of poisoning in the early manifests psychomotor agitation or disturbance of consciousness and further proceeds with the attacks of generalized seizures and the development of lactic acidosis. Consequences of intoxication may be hypoglycemia, shock, rhabdomyolysis, hemolysis, acute necrosis of skeletal muscles, DIC, bone marrow suppression and multi-organ failure.

Treatment.If you suspect significant toxicity (> 80 mg/kg of body weight thioctic acid) is shown immediate hospitalization and carrying out the common measures (for example, artificial vomiting, gastric lavage, administration of activated charcoal). Treatment of seizures generalized seizures, lactic acidosis and other consequences of intoxication, life-threatening patient should focus on the modern principles of intensive therapy and carry out symptomatic. By this time, there are no data on the feasibility of hemodialysis, hemoperfusion or hemofiltration methods in the framework of forced withdrawal of thioctic acid.

Side effects

by the Central nervous system:in some cases, changes or disturbances of taste, headache, hot flashes, excessive sweating, shortness of breath, increased intracranial pressure, dizziness, convulsions, visual impairment and double vision. In most cases, all these symptoms pass on their own.

from the digestive tract:in some cases, with the rapid introduction of the drug, there was nausea, vomiting, diarrhea, abdominal pain, which took place independently.

by blood:in selected cases petechial hemorrhages in mucous membranes/skin, platelet dysfunction, hypocoagulation, hemorrhagic rash (purpura), thrombophlebitis.

Metabolic disturbances:as a result of improved glucose uptake in some cases may decrease the level of sugar in the blood, which may cause symptoms similar to hypoglycemia, such as dizziness, sweating, headache, disorders of vision.

from the immune system:in isolated cases, skin rash, urticaria, itching, eczema, as well as systemic reactions up to the development of anaphylactic shock.

from the cardiovascular system:with the rapid introduction of pain may be observed in the heart, tachycardia, pass independently.

Others.IN rare cases it was reported reaction at the injection site, and weakness.


shelf Life

4 years.

storage Conditions

Store in a dark place at a temperature not exceeding 25 ° C.

keep out of reach of children.

keep Bottles in their original packaging for immediate use.



a Solution of ?-lipoic acid is incompatible with glucose solution, ringer solution and solutions which can react with SH groups or disulfide bonds.

Do not use in conjunction with preparations containing metal compounds (e.g. iron, magnesium).



1 bottle or 10 bottles of 50 ml each, together with protective (s) black (s) bags (s) in a carton. 


Category vacation

According to the recipe.



Salutem Farmaceutiche Erzeugnisse GmbH, Germany.

the location of the manufacturer and the address of the place of business.

Industriestrasse 3, 34212 Melsungen, Germany.


Novonorm tablets of 2 mg №30 – the drug that reduces blood sugar levels and blocking potassium ATP-dependent channels. The main active ingredient of the product is Repaglinide. The substance stimulates the pancreas 1st phase of secretion.

the Purpose and pharmacological action

the Medication is used for:

  • Combination therapy with Metformin thiazolidinedione or in the case of ineffective monotherapy.
  • Treatment of people with type II diabetes who were not helped by diet therapy.

patients taking Novonorm, may not adhere to such a strict diet, as during the use of other hypoglycemic oral drugs.

Dosage and method of application

the Tablets are intended for oral administration. The medicine should be drunk 15-20 minutes before meals. The dosage for each patient should be chosen individually depending on the baseline level of glucose in the blood. 

Adjustment rules is done once a week. The recommended starting dosage is 0.5 mg (1/4 tablet). The maximum single rate of the drug should not exceed 4 mg (2 tablets), and the daily – 16 mg (8 tablets). The course of therapy is on average a month, but can be adjusted by the attending physician depending on the patient's condition and the amount of glucose in the blood.

Write a review

Note: HTML is not translated!
    Bad           Good

Recently viewed © 2019